NASDAQ:IMCR Immunocore Q3 2025 Earnings Report $30.50 -0.79 (-2.51%) As of 11:58 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Immunocore EPS ResultsActual EPS$0.02Consensus EPS -$0.30Beat/MissBeat by +$0.32One Year Ago EPS$0.17Immunocore Revenue ResultsActual Revenue$103.69 millionExpected Revenue$137.29 millionBeat/MissMissed by -$33.60 millionYoY Revenue Growth+29.20%Immunocore Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateThursday, November 6, 2025Conference Call Time4:00PM ETUpcoming EarningsImmunocore's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 2:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Immunocore Earnings HeadlinesImmunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesSeptember 22 at 4:29 AM | americanbankingnews.comImmunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14, 2026 | seekingalpha.comBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.September 25 at 1:00 AM | Decentralized Masters (Ad)Immunocore Completes Enrollment in Study of Potential Advanced Melanoma TreatmentSeptember 14, 2026 | finance.yahoo.comImmunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanomaSeptember 14, 2026 | globenewswire.comImmunocore to present at upcoming investor conferencesSeptember 1, 2026 | globenewswire.comSee More Immunocore Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immunocore? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunocore and other key companies, straight to your email. Email Address About ImmunocoreImmunocore (NASDAQ:IMCR) Holdings plc is a biotechnology company that develops T-cell receptor (TCR) therapies designed to direct the immune system against cancer and other serious diseases. Its ImmTAC platform uses engineered TCRs to recognize disease-related peptides presented on the surface of cells and recruit T cells to destroy targeted cells. The company’s lead product is KIMMTRAK (tebentafusp-tebn), an ImmTAC therapy approved in the United States, European Union and other markets for the treatment of unresectable or metastatic uveal melanoma in certain patients. KIMMTRAK is designed to target gp100, a protein expressed by melanoma cells, and activate T cells against the tumor. Immunocore is headquartered in Abingdon, United Kingdom, and serves international markets through its commercial and development activities. In addition to uveal melanoma, the company is advancing a pipeline of ImmTAC candidates being studied in other cancers, as well as exploring potential applications in infectious and autoimmune diseases. Bahija Jallal has served as Immunocore’s chief executive officer since 2019. The company was founded in the United Kingdom and became publicly traded on the Nasdaq Stock Market in 2021 under the symbol IMCR.View Immunocore ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Super Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketOil May Be Stronger Than It Looks—And Diamondback Is on SaleBlackBerry Shifts Gears With Coretura DealCintas Raises Guidance as a Major Catalyst Moves Closer3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure Builds Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
